Previous 10 | Next 10 |
Agenus (NASDAQ: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, today announced that Dr. Garo Armen, Chairman and CEO, will participate in the following upcoming investor conferences: HC Wainwright BioConnect Investor Con...
2023-04-17 13:55:29 ET Biopharmaceutical stocks were trending higher across the board Monday morning, thanks to Merck 's (NYSE: MRK) nearly $11 billion buyout offer for Prometheus Biosciences (NASDAQ: RXDX) . So far, some of the day's biggest winners have been the cancer...
2023-04-17 08:21:48 ET Agenus ( NASDAQ: AGEN ) announced Monday that the FDA granted Fast Track Designation for a combination therapy containing its anti-CTLA-4 compound botensilimab (AGEN1181) and anti-PD-1 molecule balstilimab (AGEN2034) as a treatment for certain colorectal cance...
Agenus Inc. (Nasdaq: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, has been granted Fast Track Designation from the US Food and Drug Administration (FDA) for the investigation of the combination of botensilimab (AGEN1181) and bal...
BETHESDA, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced the appointment of C. Evan Ballant...
2023-04-04 15:53:30 ET U.S. stock markets are under heavy pressure today after two reports on job openings and factory orders came in weaker than expected. The key issue at play is a growing concern that the Federal Reserve's rate hiking campaign may spark a deep and long-lasting economic d...
Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that its Board of Directors has declared a dividend of 5 million shares of common stock of its subsidiary, MiNK Therapeutics, Inc. (“MiNK&...
Data presented at plenary session of Society of Gynecologic Oncology Meeting Patients treated suffered from platinum resistant/refractory ovarian cancer Previous PD-(L)1/CTLA-4 combinations have reported only 3-10% responses in comparable patient populations 1,2 Fi...
2023-03-23 12:21:25 ET Shares of the clinical-stage immunotherapy company Agenus (NASDAQ: AGEN) fell by 11.7% during the first three and half days of trading this week, according to data provided by S&P Global Market Intelligence . The biotech's stock has been trending l...
2023-03-21 11:49:00 ET Summary Botensilimab is engineered for major improvements over earlier CTLA-4 agents. Melanoma, colorectal and pancreatic cancer Phase 2 trial enrollments should complete in 2023. An application to the FDA for commercial approval could come as early as 2...
News, Short Squeeze, Breakout and More Instantly...
Extended BOT/BAL Therapy Yields Pronounced Improvements in Tumor Reductions Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results from an investigator-sponsored trial (IST) of botensilim...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using botensilimab (BOT), a huma...
2024-06-27 01:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...